Dryden M, Dickinson A, Brooks J, Hudgell L, Saeed K, Cutting K F
Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
Winchester and Rare and Imported Pathogens Dept PHE, Porton, UK.
J Wound Care. 2016 Mar;25(3):140, 142-6. doi: 10.12968/jowc.2016.25.3.140.
This article reports the outcomes of the use of Surgihoney RO (SHRO), topical wound dressing in a multi-centre, international setting. The aims were to explore the clinical effects of SHRO, including a reduction in bacterial load and biofilm and improvement in healing in a variety of challenging non-healing and clinically infected wounds.
This was a non-comparative evaluation, where both acute and chronic wounds with established delayed healing were treated with the dressing. Clinicians prospectively recorded wound improvement or deterioration, level of wound exudate, presence of pain, and presence of slough and necrosis. Analysis of this data provided information on clinical performance of the dressing. Semi-quantitative culture to assess bacterial bioburden was performed where possible.
We recruited 104 patients, mean age 61 years old, with 114 wounds. The mean duration of wounds before treatment was 3.7 months and the mean duration of treatment was 25.7 days. During treatment 24 wounds (21%) healed and the remaining 90 (79%) wounds improved following application of the dressing. No deterioration in any wound was observed. A reduction in patient pain, level of wound exudate and in devitalised tissue were consistently reported. These positive improvements in wound progress were reflected in the wound cultures that showed a reduction in bacterial load in 39 out of the 40 swabs taken. There were two adverse events recorded: a stinging sensation following application of the dressing was experienced by 2 patients, and 2 elderly patients died of causes unrelated to the dressing or to the chronic wound. These patients' wounds and their response to SHRO have been included in the analysis.
SHRO was well tolerated and shows great promise as an effective potent topical antimicrobial in the healing of challenging wounds.
Matthew Dryden has become a shareholder in Matoke Holdings, the manufacturer of Surgihoney RO, since the completion of this study. Keith Cutting is a consultant to Matoke Holdings.
本文报告了在多中心国际环境中使用外科蜂蜜RO（SHRO）这种局部伤口敷料的结果。目的是探讨SHRO的临床效果，包括减少细菌载量和生物膜，以及促进各种具有挑战性的难愈合和临床感染伤口的愈合。
这是一项非对照评估，使用该敷料治疗急性和慢性且已出现愈合延迟的伤口。临床医生前瞻性地记录伤口的改善或恶化情况、伤口渗出液水平、疼痛情况以及是否存在腐肉和坏死。对这些数据的分析提供了有关该敷料临床性能的信息。在可能的情况下进行半定量培养以评估细菌生物负荷。
我们招募了104名患者，平均年龄61岁，有114处伤口。治疗前伤口的平均持续时间为3.7个月，平均治疗时间为25.7天。治疗期间，24处伤口（21%）愈合，其余90处伤口（79%）在使用敷料后有所改善。未观察到任何伤口恶化。患者的疼痛、伤口渗出液水平和失活组织均持续减少。伤口进展的这些积极改善反映在伤口培养结果中，40份拭子中有39份显示细菌载量减少。记录了两起不良事件：2名患者在使用敷料后有刺痛感，2名老年患者死于与敷料或慢性伤口无关的原因。这些患者的伤口及其对SHRO的反应已纳入分析。
SHRO耐受性良好，作为一种有效的局部抗菌剂，在治疗具有挑战性的伤口方面显示出巨大潜力。
自本研究完成以来，马修·德莱登已成为SHRO制造商Matoke Holdings的股东。基思·卡特是Matoke Holdings的顾问。
